My Blog
Expert 101: Strategic Disengagement. A Professional Imperative
In multi-stakeholder health and policy work, professionals are often encouraged to lean in: to collaborate, co-create, and commit. However, there are moments when the most strategic and reputationally sound decision is to step back. This edition of Expert 101 explores...
Expert 101: Strategic Disengagement. A Professional Imperative
In multi-stakeholder health and policy work, professionals are often...
Why “Metabolic Age” Needs a Rethink. And What It Means for Obesity Care
“The story is far more complicated, and more interesting, than a single number suggests.” When people ask about...
Burnout, Breakdown, and the Midlife Reboot: Why High-Performing Women Are Rewriting the Rules of Success
Burnout is pushing many high-achieving women to rethink what success means. Midlife isn’t the end—it’s a chance to reset, reinvent, and build a more fulfilling path. Discover how women are rewriting the rules and finding new ways to thrive. #Leadership #WomenInBusiness #MidlifeReinvention
A Bottle of Water Isn’t a Luxury: Why the EU Needs a Medical ID Card for Hydration-Dependent Travellers
This summer, more than 300 million people will pass through EU airports. Many will be hot, tired, and thirsty. But for...
From ‘Skinny Jab’ to Health Equity: How Media Shapes the Obesity Treatment Debate
Over the past year, the public conversation around obesity treatment has intensified. GLP-1 receptor agonists, such as...
What’s the Difference Between “No Known Health Benefits” and “Detrimental to Your Health”?
Why Food Labelling Language Matters in the Age of Chronic Disease and Therapeutic Nutrition In today’s food...
When the Slowest Stakeholder Sets the Pace: What Sickle Cell and Thalassemia Reveal About Europe’s Rare Disease Reform
As trilogue negotiations begin on the EU’s pharmaceutical package, there’s a renewed focus on access, innovation, and...
GLP-1s and the Weight Loss Illusion: What Investors and Regulators Are Missing
GLP-1 drugs are transforming obesity treatment, but focusing solely on weight loss may be misleading. This article explores how metabolic biomarkers like inflammation and insulin sensitivity could offer a more accurate measure of success, reshaping regulatory thinking and investor strategy.
Why AI Writing Tools Are a Game-Changer for Adults with Autism and ADHD. And What EU Employers Need to Know
Let’s start with something I hear far too often:“Isn’t using AI to help with writing… cheating?” Let me be absolutely...
From Exercise to Movement: Why the WHO’s Language Shift Matters for Health Tech: and What Investors Should Be Watching
There’s been a quiet but meaningful shift in how the World Health Organization talks about physical activity. If...